Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo

Cancer Letters

Volumn 145, Issue 1-2, 1999, Pages 121-126

  Ikemoto, Shinichi ^a   Sugimura, Kazunobu ^a   Wada, Seiji ^a   Yasumoto, Ryouji ^a   Yamamoto, Keisuke ^a   Kishimoto, Taketoshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5' Deoxy 5 fluorouridine; Thymosin fraction 5; Uridine phosphorylase

Indexed keywords

DOXIFLURIDINE; THYMOSIN FRACTION 5;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLOXURIDINE; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C3H; PRODRUGS; THYMOSIN; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

ANIMALIA; RODENTIA;

EID: 0032887320     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00238-4     Document Type: Article

References (28)

1. Niitani H., Kimura K., Saito T., Nakao I., Abe O., Urushizaki I., Ohta K., Yoshida Y., Kimura T., Kurihara M., Takeda C., Taguchi T., Terasawa T., Tominaga K., Furue H., Wakui A., Ogawa N. Phase II combination study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer: multi-institutional cooperative study. Jpn. J. Cancer Chemother. 12:1985;2044-2051.
2. Armstrong R.D., Cadman E. 5′-Deoxy-5-fluorouridine selective toxicity for human cells compared to human bone marrow. Cancer Res. 43:1983;2525-2528.
3. Connolly K.M., Diasio R.B., Armstrong R.D., Kaplan A.M. Decreased immunosuppression associated with anticancer activity of 5′-deoxy-5-fluorouridine compared to 5-fluorouracil and 5-fluorouridine. Cancer Res. 43:1983;2529-2535.
4. Miyadera K., Sumizawa T., Haraguchi M., Yoshida H., Konstanty W., Yamada Y., Akiyama S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55:1995;1687-1690.
5. Miwa M., Cook A., Ishitsuka H. Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. Chem. Pharm. Bull. 34:1986;4225-4232.
6. Choong Y.S., Lee S.P., Alley P.A. Comparison of the pyrimidine nucleoside phosphorylase activity in human tumors and normal tissues. Exp. Pathol. 33:1988;23-25.
7. Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., Yamada Y., Murata F., Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 88:1996;1110-1117.
8. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Comley M., Whitehouse R.M., Talbot D.C., Gatter K.C., Harris A.L. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br. J. Cancer. 75:1997;477-481.
9. Haraguchi S., Furukawa T., Sumizawa T., Akiyama S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res. 53:1993;5680-5682.
10. Schwartz E.L., Hoffman M., O'Connor C.J., Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-( in human colon carcinoma cells. Biochem. Biophys. Res. Commun. 182:1992;1232-1239.
11. Tavaearai H.T., Laurent P.L., Suardet L., Eliason J.F., Givel J., Odartchenko N. Interactions of interferon-α2a with 5-deoxy-5-fluorouridine in colorectal cancer cells in vitro. Eur. J. Cancer. 28:1992;368-372.
12. Eda H., Fujimoto K., Watanabe S., Ura M., Hino A., Tanaka Y., Wada K., Ishitsuka H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol. 32:1993;333-338.
13. Eda H., Fujimoto K., Watanabe S., Ishikawa T., Ohiwa T., Tatsuno K., Tanaka Y., Ishitsuka H. Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn. J. Cancer Res. 84:1993;341-347.
14. Goldstein A.L., Guha A., Zatz M.M., Hardy M.A., White A. Purification and biological activity of thymosin, a hormone of the thymus gland, Proc. Natl. Acad. Sci. USA. 69:1972;1800-1803.
15. Barett D.J., Wara D.W., Ammann A.J., Cowan M.J. Thymosin therapy in the Digeorge syndrome. J. Ped. 97:1980;66-71.
16. Rubinstein A., Hirschhorn R., Sicklick M., Murphy R.A. In vivo and in vitro effects of thymosin and adenosine deaminase on adenosine-deaminase-deficient lymphocytes. New Engl. J. Med. 300:1979;387-392.
17. Cohen M.H., Chretien P.B., Ihde D.C., Fossieck B.E., Makuch R., Bunn P.A., Johnston A.V., Shackney S.E., Matthews M.J., Lipson S.D., Kenady D.E., Minna J.D. Thymosin fraction 5 and intensive combination chemotherapy prolonging the survival of patients with small-cell lung cancer. J. Am. Med. Assoc. 241:1979;1813-1815.
18. Mosmann T.J. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol. Methods. 65:1985;55-63.
19. Laurent P.L., Tevaearai H.T., Eliason J.F., Givel J.C., Odartchenko N. Interferon alfa and 5′-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumors. Eur. J. Cancer. 30:1994;1859-1865.
20. Tanaka Y., Endo M., Ouchi K., Mori K., Ishitsuka H. Augmentation of antitumor activity of 5′-deoxy-5-fluorouridine by IL-12 through the up-regulation of pyridine nucleoside phosphorylase in murine tumor models. Eur. J. Cancer 33 (Suppl. 8). 1997;S176-S177.
21. Takebayashi Y., Yamada K., Ohmoto Y., Sameshima T., Miyadera K., Yamada Y., Akiyama S., Aikou T. The correlation of thymidine phosphorylase activity with the expression of interleukin 1α, interferon α, and interferon γ in human colorectal carcinoma, Cancer Lett. 95:1995;57-62.
22. Miwa M., Sekiguchi F., Akaza H., Tokita H., Nitta K., Adachi S., Kanazawa K., Ishitsuka H. Comparative studies on the antitumor activity of fluorinated pyrimidine derivatives against human bladder, cervical and ovarian cancer xenografts in nude mice. Jpn. J. Cancer Chemother. 18:1991;1579-1586.
23. Hirano Y., Takayama T., Ushiyama T., Suzuki K., Fujita K. The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5′-DFUR. Jpn. J. Cancer Chemother. 25:1998;1779-1781.
24. Yamamoto Y., Toi M., Tominaga T. Prediction of the effect of 5′-deoxy-5-fluorouidine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol. Res. 3:1996;863-865.
25. Lopez M., Lauro L.D., Gionfra T. Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results. J. Surg. Oncol. 2:1991;108-111.
26. Garaci E., Pica F., Mastino A. Antitumor effect of thymosin α1/interleukin-2 or thymosin α1/interferon α, β following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J. Immunother. 13:1993;7-17.
27. Zatz M.M., Oliver J., Sztein M.B., Skotnicki A.B., Goldstein A.L. Comparison of the effects of thymosin and other thymic factors on modulation of interleukin-2 production. J. Biol. Response Modif. 4:1985;365-376.
28. Attia W.Y., Badamchian M., Goldstein A.L., Spangelo B.L. Thymosin stimulates interleukin-6 production from rat spleen cells in vitro. Immunopharmacology. 26:1993;171-179.